PharmEvolution international forum dedicated to the pharmaceutical industry development in Russia is to be held in Kaluga at Innovation Culture Center on April 23, 2019. This year PharmEvolution celebrates its fifth anniversary. Top managers of major pharmaceutical companies, top officials of government agencies, representatives of R&D institutions, innovative business incubators, trade associations, unions, foundations, lead analysts, investors and experts are to attend the forum.
The forum is organized by the Government of Kaluga Region, the Agency for Innovative Development – Center for Cluster Development of Kaluga Region, the Agency for Regional Development of Kaluga Region supported by Kaluga Pharmaceutical Cluster in cooperation with Kommersant Publishing House. Novo Nordisk, a leader in diabetes treatment, is a partner of PharmEvolution.
The list of key topics to be discussed at the forum includes the government strategy in the field of the pharmaceutical industry development ant its perception by business community, new provisions of the Russian law related to the pharmaceutical industry, government export strategy, pharmaceuticals’ marking, digitalization in the pharmaceutical industry; personnel training for pharmaceutical clusters, R&D practices in Russia and their development.
Kaluga Pharmaceutical cluster is one of the largest industry clusters in the Russian Federation. It consists of 64 members, including global and Russian pharmaceutical companies, innovative SMEs, leading R&D and education centers. Finished pharmaceutical products represent over 80% of all products manufactured by the cluster members. Pharmaceutical companies operating in Kaluga Region produce over 150 medicines, the production of several dozens more is to be launched in the near future. Virtually all companies expand their production volumes and commission new production lines.
Additional Information on Novo Nordisk Plant in Kaluga:
Novo Nordisk Kaluga innovative plant has launched a full cycle production of modern insulins. No similar products are manufactured in Russia. The plant produces aseptic cartridges, assembles and packs FlexPen® insulin pens. Novo Nordisk Kaluga plant uses original substance produced in Denmark. It is the only production facility in Russia offering the full range of modern insulins.
Novo Nordisk Kaluga plant is a good example of successful investments in a localized project and in the Russian pharmaceutical industry modernization. The manufacturing processes meet GMP requirements, corporate standards and the Russian legislation covering pharmaceuticals’ production. The production facility applies advanced HSE and energy efficiency solutions. The company invested over RUR 8 billion in the plant, about 300 new jobs were created. The production facility occupies a territory of 13,000 m2.
Today Novo Nordisk Kaluga plant is a Russian manufacturer which fully meets localization requirements provided for by Pharma 2020 strategy and Pharma 2030 program being under development. The company constantly improves its production facility to the benefit of its Russian patients.